Dynamic Technology Lab Private Ltd Invests $530,000 in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Dynamic Technology Lab Private Ltd bought a new stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) during the third quarter, according to its most recent disclosure with the SEC. The firm bought 23,578 shares of the company’s stock, valued at approximately $530,000.

Several other hedge funds also recently made changes to their positions in the company. Amalgamated Bank increased its holdings in shares of Nurix Therapeutics by 30.6% in the 3rd quarter. Amalgamated Bank now owns 2,182 shares of the company’s stock valued at $49,000 after acquiring an additional 511 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in Nurix Therapeutics by 31.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,330 shares of the company’s stock valued at $54,000 after acquiring an additional 559 shares during the period. GAMMA Investing LLC raised its stake in Nurix Therapeutics by 299.8% during the 2nd quarter. GAMMA Investing LLC now owns 4,566 shares of the company’s stock valued at $95,000 after acquiring an additional 3,424 shares during the last quarter. International Assets Investment Management LLC lifted its position in Nurix Therapeutics by 1,098.4% during the 3rd quarter. International Assets Investment Management LLC now owns 4,494 shares of the company’s stock worth $101,000 after acquiring an additional 4,119 shares during the period. Finally, Quest Partners LLC grew its stake in shares of Nurix Therapeutics by 21.3% in the 3rd quarter. Quest Partners LLC now owns 7,458 shares of the company’s stock valued at $168,000 after purchasing an additional 1,312 shares during the last quarter.

Nurix Therapeutics Price Performance

Shares of Nurix Therapeutics stock opened at $22.11 on Friday. The business has a 50 day moving average price of $24.02 and a 200 day moving average price of $21.75. The company has a market capitalization of $1.57 billion, a P/E ratio of -7.60 and a beta of 2.20. Nurix Therapeutics, Inc. has a 1 year low of $5.95 and a 1 year high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings results on Friday, October 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.67). The company had revenue of $12.59 million for the quarter, compared to analysts’ expectations of $13.85 million. Nurix Therapeutics had a negative net margin of 313.65% and a negative return on equity of 63.39%. As a group, research analysts expect that Nurix Therapeutics, Inc. will post -2.81 EPS for the current fiscal year.

Insiders Place Their Bets

In other Nurix Therapeutics news, CFO Houte Hans Van sold 3,546 shares of the business’s stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $24.28, for a total transaction of $86,096.88. Following the completion of the sale, the chief financial officer now owns 33,724 shares of the company’s stock, valued at approximately $818,818.72. The trade was a 9.51 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Christine Ring sold 9,050 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $24.94, for a total transaction of $225,707.00. Following the sale, the insider now directly owns 24,592 shares of the company’s stock, valued at approximately $613,324.48. This trade represents a 26.90 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 27,451 shares of company stock valued at $663,160 in the last quarter. 7.20% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

NRIX has been the subject of several analyst reports. Needham & Company LLC restated a “buy” rating and set a $29.00 price target on shares of Nurix Therapeutics in a research note on Wednesday, November 6th. Royal Bank of Canada reduced their price objective on shares of Nurix Therapeutics from $27.00 to $26.00 and set an “outperform” rating for the company in a research report on Monday, October 14th. HC Wainwright increased their target price on Nurix Therapeutics from $26.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. Jefferies Financial Group initiated coverage on Nurix Therapeutics in a report on Friday, October 11th. They issued a “buy” rating and a $41.00 target price for the company. Finally, Oppenheimer upped their price target on shares of Nurix Therapeutics from $27.00 to $30.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 4th. One equities research analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $29.40.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.